keyword
MENU ▼
Read by QxMD icon Read
search

azathioprine crohn

keyword
https://www.readbyqxmd.com/read/28523450/a-review-of-the-clinical-pharmacokinetics-pharmacodynamics-and-immunogenicity-of-vedolizumab
#1
REVIEW
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Tim Wyant, Eric Fedyk, Irving Fox
Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), vedolizumab is administered as a 300 mg intravenous infusion. Vedolizumab undergoes a rapid, saturable, non-linear, target-mediated elimination process at low concentrations and a slower, linear, non-specific elimination process at higher concentrations...
May 18, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28454852/epstein-barr-virus-positive-mucocutaneous-ulcer-in-crohn-s-disease-a-condition-to-consider-in-immunosuppressed-ibd-patients
#2
Alba Juan, Triana Lobatón, Gustavo Tapia, Míriam Mañosa, Eduard Cabré, Eugeni Domènech
Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is a little known entity that can affect the oropharyngeal mucosa, the gastrointestinal tract and the skin. The main risk factor for the development of this lesion is immunosuppression. Because its features are similar to other Epstein-Barr virus-associated lymphoproliferative disorders, a differential diagnosis can sometimes prove challenging. Here, we report the case of a man diagnosed with Crohn's disease and treated with azathioprine and infliximab who developed ulceration at the rectum that was refractory to conventional medical treatment...
March 28, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28421251/defining-the-ultrasound-longitudinal-natural-history-of-newly-diagnosed-pediatric-small-bowel-crohn-disease-treated-with-infliximab-and-infliximab-azathioprine-combination-therapy
#3
Jonathan R Dillman, Soudabeh Fazeli Dehkordy, Ethan A Smith, Michael A DiPietro, Ramon Sanchez, Vera DeMatos-Maillard, Jeremy Adler, Bin Zhang, Andrew T Trout
BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab...
April 18, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/28402454/adalimumab-vs-azathioprine-in-the-prevention-of-postoperative-crohn-s-disease-recurrence-a-geteccu-randomized-trial
#4
Antonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, Carlos Taxonera, Vicente Vega Ruiz, Ignacio Marín-Jiménez, Jordi Guardiola, Luisa Castro, María Esteve, Eva Iglesias, Daniel Ceballos, Pilar Martínez-Montiel, Javier P Gisbert, Miguel Mínguez, Ana Echarri, Xavier Calvet, Jesús Barrio, Joaquín Hinojosa, María Dolores Martín-Arranz, Lucía Márquez-Mosquera, Fernando Bermejo, Jordi Rimola, Vicente Pons, Pilar Nos
Background and Aims: Postoperative recurrence of Crohn's disease (POR-CD) is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab (ADA) and azathioprine (AZA) in this setting. Methods: We performed a phase 3, 52-week, multicenter, randomized, superiority study (APPRECIA), in which patients with ileocolic resection were randomized either to ADA 160-80-40 mg SC or AZA 2.5 mg/kg/d, both associated to metronidazole...
April 11, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28372453/coloduodenal-and-enterocutaneous-fistula-in-twins-with-crohn%C3%A2-s-disease
#5
Maíia Pilar Ballester, David Martí, Marta Maia Boscá Watts, José Martín Arévalo, Miguel Mínguez
We present the case of a pair of 45-year-old monozygotic twins (A and B) diagnosed with Crohn's disease (CD) at age 20 (A) and 22 (B) with similar presenting symptoms: diarrhea, fever and weight loss. Both of them had duodenal and ileocolonic disease (A2, L3+L4 according to Montreal classification); twin B also presented jejunal involvement and perianal disease (B1p). They received treatment with antibiotics, corticosteroids, 5-ASA, azathioprine and anti-TNF with a poor control of activity. They both developed a coloduodenal fistula that required surgery...
April 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28364315/mucosal-healing-of-crohn-s-disease-in-a-patient-with-concurrent-systemic-lupus-erythematosus-using-infliximab
#6
Yuka Kagaya, Hirotsugu Sakamoto, Tomonori Yano, Keijiro Sunada, Alan Kawarai Lefor, Toshiro Niki, Hironori Yamamoto
We describe a patient with Crohn's disease (CD) concurrent with systemic lupus erythematosus (SLE). Continuous prednisolone and cyclosporine treatment resulted in no recurrent symptoms. However, diarrhea, vomiting, and fever occurred for approximately 3 months. A colonoscopy was then performed, which showed a discontinuous cobblestone appearance and longitudinal ulcers extending from the sigmoid colon to the descending colon and distal ileum. A biopsy revealed a noncaseating granulomatous lesion in the colonic mucosa...
June 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28326566/systematic-review-with-meta-analysis-comparative-efficacy-of-biologics-for-induction-and-maintenance-of-mucosal-healing-in-crohn-s-disease-and-ulcerative-colitis-controlled-trials
#7
REVIEW
A Cholapranee, G S Hazlewood, G G Kaplan, L Peyrin-Biroulet, A N Ananthakrishnan
BACKGROUND: Mucosal healing is an important therapeutic endpoint in the management of Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the comparative efficacy of various therapies in achieving this outcome. AIM: To perform a systematic review and meta-analysis of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis. METHODS: We performed a systematic review and meta-analysis of randomised controlled trials (RCT) examining mucosal healing as an endpoint of immunosuppressives, anti-tumour necrosis factor α (anti-TNF) or anti-integrin monoclonal antibody therapy for moderate-to-severe CD or UC...
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28276819/is-there-a-role-for-thioguanine-therapy-in-ibd-in-2017-and-beyond
#8
Kirstin M Taylor, Mark G Ward, Paul A Blaker, Miles P Sparrow
Conventional thiopurines are effective for the maintenance of remission of Crohn's disease and ulcerative colitis, however, up to half of patients are intolerant or unresponsive to these medications. Thioguanine is an alternative thiopurine that has shown efficacy in inflammatory bowel disease, and is particularly useful to circumvent certain side effects associated with conventional thiopurines, for example, pancreatitis. Its association with nodular regenerative hyperplasia of the liver has hindered its widespread use...
May 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28273887/csf-1-regulates-the-function-of-monocytes-in-crohn-s-disease-patients-in-remission
#9
Juan Camilo Nieto, Carlos Zamora, Elisabet Cantó, Esther Garcia-Planella, Jordi Gordillo, Maria Angels Ortiz, Cándido Juárez, Silvia Vidal
During the flare-ups of Crohn's disease (CD) patients, circulating leukocytes actively migrate toward the inflamed sites. During the remission, the lack of symptoms does not necessarily imply immunological remission. To decipher inflammatory mechanisms still operating during CD remission, we compared the expression of chemokine receptors on monocytes from CD and healthy donors (HD), and how these differences could modulate monocyte maturation and cytokine production. Flow cytometry analysis showed a higher expression of CCR5 on monocytes from CD patients than those from HD after 24 h...
December 2017: Scientific Reports
https://www.readbyqxmd.com/read/28248209/endoscopic-recurrence-six-months-after-ileocecal-resection-in-children-with-crohn-s-disease-treated-with-azathioprine
#10
Kristyna Zarubova, Ondrej Hradsky, Ivana Copova, Blanka Rouskova, Lucie Pos, Richard Skaba, Jiri Bronsky
OBJECTIVE: Intestinal surgery is an important part of Crohn's disease (CD) treatment in children. The aim of this study was to compare the rate of endoscopic recurrence at the 6 month after ileocecal resection (ICR) in children with CD treated with azathioprine (AZA) between patients who received prior anti-tumor necrosis factor alpha (anti-TNF-α) therapy and those who were not administered this therapy. Moreover, we tried to identify the potential risk factors for disease recurrence and describe the schedule of long-term follow-up after surgery...
November 17, 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28175127/p536-combination-therapy-of-bone-marrow-mesenchymal-stromal-cells-and-azathioprine-not-affect-the-clinical-course-luminal-crohn-s-disease
#11
O Knyazev, A Parfenov, N Fadeeva, A Konoplyannikov, A Kagramanova, I Ruchkina
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28174997/p119-higher-levels-of-infliximab-may-alleviate-the-need-of-azathioprine-comedication-in-the-treatment-of-patients-with-crohn-s-disease-a-sonic-post-hoc-analysis
#12
J-F Colombel, O J Adedokun, C Gasink, K Tang, F Cornillie, G D'Haens, P Rutgeerts, W Reinisch, W Sandborn, S Hanauer
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28174954/dop071-comparison-of-endoscopic-responses-to-adalimumab-monotherapy-and-combination-therapy-with-azathioprine-in-patients-with-crohn-s-disease-a-sub-analysis-of-diamond-trial
#13
K Watanabe, T Matsumoto, S Motoya, T Hisamatsu, H Nakase, N Yoshimura, T Ishida, S Kato, T Nakagawa, M Nagahori, M Esaki, T Matsui, Y Naito, T Kanai, Y Suzuki, M Nojima, M Watanabe, T Hibi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172958/p394-prolonged-azathioprine-treatment-reduces-the-need-for-surgery-in-early-crohn-s-disease
#14
Y Qiu, R Mao, S-H Zhang, R Feng, Z-R Zeng, M-H Chen
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172953/p564-low-dose-azathioprine-improves-long-term-efficacy-of-infliximab-maintenance-treatment-in-japanese-patients-with-crohn-s-disease
#15
M Nasuno, S Motoya, K Sugiyama, M Miyakawa, H Tanaka, T Iida, K Onodera, H Nakase
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28160250/thiopurines-and-methotrexate-use-in-ibd-patients-in-a-biologic-era
#16
REVIEW
Gerassimos J Mantzaris
Although we have been living in the era of biologic therapy for several decades, the use of immunomodulators (primarily thiopurines [azathioprine and mercaptopurine] and less so methotrexate) still remains an important component of the inflammatory bowel disease (IBD) pharmaceutical arsenal. Thiopurines as monotherapy exert corticosteroid-sparing effects and can maintain long-term remission in a considerable proportion of patients who have frequent relapses and are or have become mesalazine and/or corticosteroid intolerant or refractory...
March 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/28147380/promises-and-dangers-of-combination-therapy
#17
REVIEW
Wolfgang Kruis, Phuong G Nguyen, Julia Morgenstern
The efficiency of the existing methods of treating inflammatory bowel disease (IBD) is limited. There are 2 ways to address this problem - either create new treatment modalities or optimize current therapies. Optimisation may be accomplished by using combinations of established therapeutic strategies. With regard to topically acting compounds such as 5-aminosalicylic acid, combining oral and rectal preparations is a commonly used method. Another commonly used combination is anti-tumor necrosis factor (TNF)-α antibody modalities together with immunosuppressants (thiopurines, methotrexate)...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28129286/methotrexate-for-refractory-crohn-s-disease-compared-with-thiopurines-a-retrospective-non-head-to-head-controlled-study
#18
Zicheng Huang, Kang Chao, Miao Li, Min Zhi, Jian Tang, Pinjin Hu, Xiang Gao
BACKGROUND: This study assessed the efficacy and safety of methotrexate (MTX) compared with thiopurines (TPs) for refractory Crohn's disease. METHODS: Fifty-one consecutive patients who were refractory or intolerant to TPs and steroid-dependent were retrospectively analyzed. MTX (20 mg/wk, subcutaneous) was adopted for inducing and maintaining clinical remission (CR). Fifty-seven patients who were naive to immunosuppressant and prescribed azathioprine (2 mg·kg·d) or mercaptopurine (1 mg·kg·d) were simultaneously recruited...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28093426/oesophageal-presentation-of-crohn-s-disease
#19
Sara Monteiro, Maria João Moreira, José Manuel Ribeiro, José Cotter
Crohn's disease (CD) is characterised by a transmural inflammatory process, which can affect any part of the digestive tract; however, CD with oesophageal presentation is rare. We report a case of a previously healthy young woman with symptoms of dysphagia, odynophagia, chest pain and weight loss, who presented oesophageal ulcers at upper endoscopy and whose histology revealed granulomatous oesophagitis. After complementary study, a mild ileocaecal involvement of CD was demonstrated. The patient became asymptomatic with proton pump inhibitor and a course of prednisolone...
January 16, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28088612/alterations-in-cytokine-gene-expression-profile-in-colon-mucosa-of-inflammatory-bowel-disease-patients-on-different-therapeutic-regimens
#20
Tsvetelina Velikova, Dobroslav Kyurkchiev, Zoya Spassova, Iliya Karakolev, Ekaterina Ivanova-Todorova, Iskra Altankova, Spaska Stanilova
Inflammatory bowel disease (IBD) is assumed to be caused by genetic and environmental factors that interact together in promoting intestinal immune dysregulation where cytokines have validated role. However, the underlying intimate mechanisms in the human IBD involving cytokines still needs to be supplemented especially in the clinical context. The aim of this study was to investigate the expression of some inflammatory and regulatory cytokines (IL-17A, IL-23, IL-6, TGFβ1, and IL-10) as well as of the transcription factor FoxP3 in mucosal samples of IBD and non-IBD patients...
April 2017: Cytokine
keyword
keyword
30477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"